PYY, peptide YY, 5697

N. diseases: 88; N. variants: 14
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0028754
Disease: Obesity
Obesity
0.400 GeneticVariation disease BEFREE Changes in PYY concentrations were examined in obese patients after bariatric surgery and compared to healthy controls. 30639417 2019
CUI: C0028754
Disease: Obesity
Obesity
0.400 Biomarker disease BEFREE The Role of Neuropeptide Y and Peptide YY in the Development of Obesity via Gut-brain Axis. 30678628 2019
CUI: C0028754
Disease: Obesity
Obesity
0.400 Biomarker disease BEFREE As PYY analogs are under development for treatment of obesity, we aimed to clarify the relationship between PYY and bone mass. 31306808 2019
CUI: C0028754
Disease: Obesity
Obesity
0.400 Biomarker disease BEFREE Peptide-YY (PYY) and Glucagon-Like Peptide-1 (GLP-1) play important roles in the regulation of food intake and insulin secretion, and are of translational interest in the field of obesity and diabetes. 29311617 2018
CUI: C0028754
Disease: Obesity
Obesity
0.400 Biomarker disease BEFREE Therefore, the current review aims to compile, evaluate and summarise current knowledge on PYY, with particular emphasis on obesity and diabetes treatment, and the importance of specific Y receptor interactions for this. 29412828 2018
CUI: C0028754
Disease: Obesity
Obesity
0.400 AlteredExpression disease BEFREE Furthermore, prebiotics influence metabolism, and in obesity they increase the expression of anorexigenic gut hormones such as peptide tyrosine tyrosine, glucagon-like peptide 1 and leptin, as well as decrease levels of orexigenic hormones such as ghrelin. 29883788 2018
CUI: C0028754
Disease: Obesity
Obesity
0.400 Biomarker disease BEFREE FFAs are candidate drug targets for increasing the secretion of intestinal hormones such as glucagon-like peptide-1 and peptide YY as potential new treatments for type 2 diabetes and obesity. 29688303 2018
CUI: C0028754
Disease: Obesity
Obesity
0.400 Biomarker disease BEFREE In recent years peptide YY (PYY) has attracted attention within the area of diabetes and obesity due to its involvement in food intake regulation and glucose homeostasis. 30399314 2018
CUI: C0028754
Disease: Obesity
Obesity
0.400 Biomarker disease BEFREE GLP-1 and PYY are higher during the light cycle in LEAN animals and AMY is higher in the OBESE group throughout the light/dark cycle. 29191090 2017
CUI: C0028754
Disease: Obesity
Obesity
0.400 Biomarker disease BEFREE PYY and GLP-1 are implicated in regulation of gut motility, food intake and insulin secretion, and are of great interest regarding obesity and type 2 diabetes. 27405092 2017
CUI: C0028754
Disease: Obesity
Obesity
0.400 Biomarker disease BEFREE Gastrointestinal peptides such as peptide YY (PYY) can regulate appetite, which is relevant to the study of obesity. 28626523 2017
CUI: C0028754
Disease: Obesity
Obesity
0.400 Biomarker disease BEFREE In conclusion, adiponectin and omentin from subcutaneous fat displayed correlations with decreased obesity and increased insulin sensitivity while visfatin showed an association with serum PYY and weight gain. 25453978 2014
CUI: C0028754
Disease: Obesity
Obesity
0.400 Biomarker disease BEFREE RESEARCH DESIGN AND METHODS We studied 35 monozygotic (MZ) and 75 dizygotic (DZ) twin pairs (discordant and concordant for obesity) to determine the heritability of glucagon-like peptide 1 (GLP-1) responses to an oral glucose tolerance test (OGTT) and the influence of acquired obesity to GLP-1, glucose-dependent insulinotropic peptide (GIP), and peptide YY (PYY) during OGTT or meal test. 23990519 2014
CUI: C0028754
Disease: Obesity
Obesity
0.400 Biomarker disease BEFREE The discovery of this alternative circuit that regulates ingestive behavior without inducing taste aversion may open the possibility of a therapeutic application of PYY for the treatment of obesity via direct oral application. 24259562 2013
CUI: C0028754
Disease: Obesity
Obesity
0.400 GeneticVariation disease BEFREE Functional genetic variation at the PYY locus influences multiple heritable metabolic syndrome traits, likely conferring susceptibility to obesity and subsequent cardiorenal disease. 19820027 2009
CUI: C0028754
Disease: Obesity
Obesity
0.400 Biomarker disease BEFREE To verify whether peptide YY (PYY) and its Y2 receptor (Y2R) gene variants can be associated with obesity or hypertension or both in a cohort of obese children and adolescents. 18622237 2008
CUI: C0028754
Disease: Obesity
Obesity
0.400 Biomarker disease BEFREE PYY, along with few other gut hormones, has been suggested as a potential therapeutic agent for obesity. 18441153 2008
CUI: C0028754
Disease: Obesity
Obesity
0.400 Biomarker disease BEFREE In this study, we aimed to assess whether low fasting and postprandial PYY secretion is an early defect, potentially promoting the development of obesity and T2D, and whether it is modified by macronutrient content. 18317469 2008
CUI: C0028754
Disease: Obesity
Obesity
0.400 GeneticVariation disease BEFREE These results provide evidence of association for NPY2R and PYY gene variants with obesity and none for PPY variants. 17235527 2007
CUI: C0028754
Disease: Obesity
Obesity
0.400 Biomarker disease CTD_human A PYY Q62P variant linked to human obesity. 16368708 2006
CUI: C0028754
Disease: Obesity
Obesity
0.400 GeneticVariation disease BEFREE Taken together, these results are the first to support that rare sequence variants within PYY can influence human susceptibility to obesity. 16368708 2006
CUI: C0028754
Disease: Obesity
Obesity
0.400 GeneticVariation disease BEFREE Mutations in the human PYY and Y2 receptor genes may contribute to the development of obesity. 16756746 2006
CUI: C0028754
Disease: Obesity
Obesity
0.400 AlteredExpression disease BEFREE Together, these findings suggest that low circulating levels of PYY could contribute to hyperinsulinemia and insulin resistance, and possibly contribute to subsequent development of obesity and type 2 diabetes. 17045646 2006
CUI: C0028754
Disease: Obesity
Obesity
0.400 GeneticVariation disease BEFREE We found no association to obesity for the PYY Arg72Thr polymorphism, which is located nearby the essential carboxy terminal. 16331299 2006
CUI: C0028754
Disease: Obesity
Obesity
0.400 Biomarker disease BEFREE Our findings suggest that modulating the release of endogenous satiety factors, such as PYY, through alteration of specific diet constituents could provide a rational therapy for obesity. 16950139 2006